Patheon and Procaps have signed an agreement to provide a range of prescription pharmaceutical soft-gel product development and manufacturing services. The offering will be branded as 'P-Gels' soft gels and the partnership will give Patheon rights to market Procaps' soft gel technology and manufacturing capabilities in North America, Europe and Asia.
The capabilities Patheon gains via the P-Gels offering include large-scale commercial supply of prescription soft gel capsules for the North American, European and Asian markets. Procaps has been developing and manufacturing soft gel capsules since 1977 and currently has capacity to manufacture up to nine billion capsules per year.
The soft gel dosage form claims to provide key advantages for drug-delivery and consumer experience. It offers rapid and consistent absorption of drugs and consistent delivery of highly potent drugs that require small dosages. In many cases, soft gels can be used to improve the solubility of drugs that pose bioavailability challenges. Consumer advantages include reliable delivery, taste masking, ease of swallowing and rapid onset.